Cheryl H. Arrowsmith

Cheryl H. Arrowsmith

SGC Toronto

Arrowsmith

Biography

Cheryl Arrowsmith is a Senior Scientist at the Princess Margaret Cancer Centre, Professor in the Department of Medical Biophysics, University of Toronto, and the Chief Scientist of the Structural Genomics Consortium (SGC) at the University of Toronto.  Her research focuses on the structural and chemical biology of chromatin and epigenetic regulatory factors especially as relates to cancer and drug discovery. In partnership with major pharmaceutical companies, she leads the SGC’s international open science program that is developing and distributing unencumbered Chemical Probes that support the discovery of new medicines. She received her Ph.D. from the University of Toronto and carried out postdoctoral research at Stanford University, and was co-founder of Affinium Pharmaceuticals, which developed a new medicine for multidrug resistant bacteria. She has published over 300 research articles and was recognized by Clarivate Analytics as being among the worlds top 1% of highly cited scientists in 2018, 2019 and 2022. She was elected an AAAS Fellow (2015), and a Fellow of the Royal Society of Canada (2020).

2011

Zn-binding AZUL domain of human ubiquitin protein ligase Ube3A.

Lemak A, Yee A, Bezsonova I, Dhe-Paganon S, Arrowsmith CH

J. Biomol. NMR. 2011-9-27 . 51(1-2):185-90 .doi: 10.1007/s10858-011-9552-y

PMID: 21947926

Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.

Liu F, Barsyte-Lovejoy D, Allali-Hassani A, He Y, Herold JM, Chen X, Yates CM, Frye SV, Brown PJ, Huang J, Vedadi M, Arrowsmith CH, Jin J

J. Med. Chem.. 2011-9-8 . 54(17):6139-50 .doi: 10.1021/jm200903z

PMID: 21780790

A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells.

Vedadi M, Barsyte-Lovejoy D, Liu F, Rival-Gervier S, Allali-Hassani A, Labrie V, Wigle TJ, Dimaggio PA, Wasney GA, Siarheyeva A, Dong A, Tempel W, Wang SC, Chen X, Chau I, Mangano TJ, Huang XP, Simpson CD, Pattenden SG, Norris JL, Kireev DB, Tripathy A, Edwards A, Roth BL, Janzen WP, Garcia BA, Petronis A, Ellis J, Brown PJ, Frye SV, Arrowsmith CH, Jin J

Nat. Chem. Biol.. 2011-7-10 . 7(8):566-74 .doi: 10.1038/nchembio.599

PMID: 21743462

Recognition of multivalent histone states associated with heterochromatin by UHRF1 protein.

Nady N, Lemak A, Walker JR, Avvakumov GV, Kareta MS, Achour M, Xue S, Duan S, Allali-Hassani A, Zuo X, Wang YX, Bronner C, Chédin F, Arrowsmith CH, Dhe-Paganon S

J. Biol. Chem.. 2011-7-8 . 286(27):24300-11 .doi: 10.1074/jbc.M111.234104

PMID: 21489993

Small-molecule ligands of methyl-lysine binding proteins.

Herold JM, Wigle TJ, Norris JL, Lam R, Korboukh VK, Gao C, Ingerman LA, Kireev DB, Senisterra G, Vedadi M, Tripathy A, Brown PJ, Arrowsmith CH, Jin J, Janzen WP, Frye SV

J. Med. Chem.. 2011-4-14 . 54(7):2504-11 .doi: 10.1021/jm200045v

PMID: 21417280

Interferon-inducible protein 16: insight into the interaction with tumor suppressor p53.

Liao JC, Lam R, Brazda V, Duan S, Ravichandran M, Ma J, Xiao T, Tempel W, Zuo X, Wang YX, Chirgadze NY, Arrowsmith CH

Structure. 2011-3-9 . 19(3):418-29 .doi: 10.1016/j.str.2010.12.015

PMID: 21397192

Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.

Yap DB, Chu J, Berg T, Schapira M, Cheng SW, Moradian A, Morin RD, Mungall AJ, Meissner B, Boyle M, Marquez VE, Marra MA, Gascoyne RD, Humphries RK, Arrowsmith CH, Morin GB, Aparicio SA

Blood. 2011-2-24 . 117(8):2451-9 .doi: 10.1182/blood-2010-11-321208

PMID: 21190999

Structural and functional comparison of the RING domains of two p53 E3 ligases, Mdm2 and Pirh2.

Shloush J, Vlassov JE, Engson I, Duan S, Saridakis V, Dhe-Paganon S, Raught B, Sheng Y, Arrowsmith CH

J. Biol. Chem.. 2011-2-11 . 286(6):4796-808 .doi: 10.1074/jbc.M110.157669

PMID: 21084285

Recognition and specificity determinants of the human cbx chromodomains.

Kaustov L, Ouyang H, Amaya M, Lemak A, Nady N, Duan S, Wasney GA, Li Z, Vedadi M, Schapira M, Min J, Arrowsmith CH

J. Biol. Chem.. 2011-1-7 . 286(1):521-9 .doi: 10.1074/jbc.M110.191411

PMID: 21047797

2010

Structural basis of E2-25K/UBB+1 interaction leading to proteasome inhibition and neurotoxicity.

Ko S, Kang GB, Song SM, Lee JG, Shin DY, Yun JH, Sheng Y, Cheong C, Jeon YH, Jung YK, Arrowsmith CH, Avvakumov GV, Dhe-Paganon S, Yoo YJ, Eom SH, Lee W

J. Biol. Chem.. 2010-11-12 . 285(46):36070-80 .doi: 10.1074/jbc.M110.145219

PMID: 20826778